Chidamide联合环磷酰胺、Vindesine、泼尼松和依托泊苷治疗老年人侵袭性自然杀伤细胞白血病的急性和持续缓解

IF 1.5 4区医学 Q3 HEMATOLOGY

Turkish Journal of Hematology Pub Date : 2023-08-31 Epub Date: 2023-07-19 DOI:10.4274/tjh.galenos.2023.2023.0227

Qingqing Lin, Renzhi Pei, Ying Lu

{"title":"Chidamide联合环磷酰胺、Vindesine、泼尼松和依托泊苷治疗老年人侵袭性自然杀伤细胞白血病的急性和持续缓解","authors":"Qingqing Lin, Renzhi Pei, Ying Lu","doi":"10.4274/tjh.galenos.2023.2023.0227","DOIUrl":null,"url":null,"abstract":"Aggressive natural killer cell leukemia (ANKL) is a fulminant disease with a median overall survival of 2 months [1,2]. Although induction therapy with an L-asparaginase-based combined chemotherapy regimen followed by allogeneic hematologic stem cell transplantation improves clinical survival, the overall success of this approach appears rather limited [3,4]. This limitation is even more pronounced in older patients who are unable to tolerate intensive chemotherapy. Histone deacetylase inhibitors have been identified by Dufva et al. [5] as ideal drug candidates in the management of ANKL. Here we report a case of an older patient with ANKL who was treated successfully with chidamide combined with conventional chemotherapy with no significant toxicity arising.","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":"40 3","pages":"225-226"},"PeriodicalIF":1.5000,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/f1/TJH-40-225.PMC10476257.pdf","citationCount":"1","resultStr":"{\"title\":\"Acute and Persistent Remission of Aggressive Natural Killer Cell Leukemia in an Older Patient Induced by Chidamide Combined with Cyclophosphamide, Vindesine, Prednisone, and Etoposide Therapy\",\"authors\":\"Qingqing Lin, Renzhi Pei, Ying Lu\",\"doi\":\"10.4274/tjh.galenos.2023.2023.0227\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aggressive natural killer cell leukemia (ANKL) is a fulminant disease with a median overall survival of 2 months [1,2]. Although induction therapy with an L-asparaginase-based combined chemotherapy regimen followed by allogeneic hematologic stem cell transplantation improves clinical survival, the overall success of this approach appears rather limited [3,4]. This limitation is even more pronounced in older patients who are unable to tolerate intensive chemotherapy. Histone deacetylase inhibitors have been identified by Dufva et al. [5] as ideal drug candidates in the management of ANKL. Here we report a case of an older patient with ANKL who was treated successfully with chidamide combined with conventional chemotherapy with no significant toxicity arising.\",\"PeriodicalId\":23362,\"journal\":{\"name\":\"Turkish Journal of Hematology\",\"volume\":\"40 3\",\"pages\":\"225-226\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/f1/TJH-40-225.PMC10476257.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turkish Journal of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4274/tjh.galenos.2023.2023.0227\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/tjh.galenos.2023.2023.0227","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Acute and Persistent Remission of Aggressive Natural Killer Cell Leukemia in an Older Patient Induced by Chidamide Combined with Cyclophosphamide, Vindesine, Prednisone, and Etoposide Therapy

Aggressive natural killer cell leukemia (ANKL) is a fulminant disease with a median overall survival of 2 months [1,2]. Although induction therapy with an L-asparaginase-based combined chemotherapy regimen followed by allogeneic hematologic stem cell transplantation improves clinical survival, the overall success of this approach appears rather limited [3,4]. This limitation is even more pronounced in older patients who are unable to tolerate intensive chemotherapy. Histone deacetylase inhibitors have been identified by Dufva et al. [5] as ideal drug candidates in the management of ANKL. Here we report a case of an older patient with ANKL who was treated successfully with chidamide combined with conventional chemotherapy with no significant toxicity arising.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Turkish Journal of Hematology HEMATOLOGY-

CiteScore

2.90

自引率

3.80%

发文量

审稿时长

1 months

期刊介绍： The Turkish Journal of Hematology is published quarterly (March, June, September, and December) by the Turkish Society of Hematology. It is an independent, non-profit peer-reviewed international English-language periodical encompassing subjects relevant to hematology. The Editorial Board of The Turkish Journal of Hematology adheres to the principles of the World Association of Medical Editors (WAME), International Council of Medical Journal Editors (ICMJE), Committee on Publication Ethics (COPE), Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). The aim of The Turkish Journal of Hematology is to publish original hematological research of the highest scientific quality and clinical relevance. Additionally, educational material, reviews on basic developments, editorial short notes, images in hematology, and letters from hematology specialists and clinicians covering their experience and comments on hematology and related medical fields as well as social subjects are published. As of December 2015, The Turkish Journal of Hematology does not accept case reports. Important new findings or data about interesting hematological cases may be submitted as a brief report.